Overdose has not been reported.
None known
Gastrointestinal disorders:
Mild gastrointestinal events such as nausea, vomiting, diarrhoea, and abdominal pain have been reported. Frequency not known (cannot be estimated from data).
Immune system disorders:
Hypersensitivity reactions have been reported (mainly after parenteral administration). Allergic and anaphylactic reactions, with symptoms of pruritus, urticaria, itching, hives, angioedema, abdominal pain, respiratory distress, tachycardia, palpitations, and shock have been reported in single cases. Frequency not known (cannot be estimated from data).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme; Website: www.mhra.gov.uk/yellowcard.
No relevant data
Treatment of Avitron-V deficiency
ATC Code: A11DA01
Pharmacotheraputic Group: Vitamin B1, Plain
Avitron-V is an essential co-enzyme for carbohydrate metabolism.
Avitron-V is well absorbed from the gastrointestinal tract following oral administration, although the absorption of large doses is limited. It is widely distributed to most body tissues and appears in breast milk. Within the cell, Avitron-V is mostly present as the diphosphate. Avitron-V is not stored to any appreciable extent in the body; amounts in excess of the body's requirements are excreted in the urine as unchanged Avitron-V or metabolites.
This medicinal product contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
This medicinal product also contains sucrose. Patients with rare hereditary problems of fructose intolerance, malabsorption or sucrose-isomaltase insufficiency should not take this medicine
No studies on the effect on the ability to drive and use machines have been performed. However, patients should be cautioned to see how they react before driving or operating machinery.
Adults, the Elderly and Children over three years:
Mild chronic deficiency: 50mg daily
Severe deficiency: 100mg three times daily.
Not recommended for children under three years.
Route of administration: oral
None
